|
|
|
|
Archives
|
Entry
|
Author
|
Date
|
Location
|
|
The Convergence of Biology, Medicine, and Engineering
|
Robert Langer |
01/18/12 |
Boston
|
|
The Boston Life Sciences Newsmakers: Civitas, Blend, Forma, & More
|
Erin Kutz |
01/13/12 |
Boston
|
|
LogMeIn, Safari, Forma, And More Behind the Boston-Area Deals News
|
Erin Kutz |
01/11/12 |
Boston
|
|
Langer, Farokhzad Start New Combo Drug Company, Blend Therapeutics
|
Luke Timmerman |
01/06/12 |
Boston
|
|
Editor’s Picks: Xconomy Boston’s Top 20ish Stories of 2011
|
Gregory T. Huang |
12/28/11 |
Boston
|
|
Best Buy Picks Up MindShift, Termeer Funds NanoString, Basho Adds $5M More, & More Boston-Area Deals News
|
Erin Kutz |
11/09/11 |
Boston
|
|
Langer Nabs Cash From Rock Stars, Verastem Seeks $50M IPO, Alnylam Snags RNAi Collab, & More Boston-Area Life Sciences News
|
Erin Kutz |
11/04/11 |
Boston
|
|
Bob Langer’s Latest Project: Fix Damaged Vocal Cords for Rock Stars, Cancer Patients
|
Luke Timmerman |
11/02/11 |
Boston
|
|
Editor’s Picks: Xconomy Boston’s Top 20 Stories of the Third Quarter
|
Gregory T. Huang |
10/28/11 |
Boston
|
|
BIND and Selecta Pull in $50M from Russian Fund Seeking to Advance Nano-Drugs
|
Arlene Weintraub |
10/27/11 |
Boston
|
|
Xconomist of the Week: Bob Langer’s Advice for Turning Foundation and Government Money into Startup Success
|
Arlene Weintraub |
09/01/11 |
Boston
|
|
T2 Biosystems Closes $23M More for Fast, Cheap Diagnostic Tools
|
Gregory T. Huang |
08/10/11 |
Boston
|
|
Biogen Eyes Cambridge Move, Vertex Licenses Alios Drugs, Concert Nabs GSK Payment, & More Boston-Area Life Sciences News
|
Erin Kutz |
06/24/11 |
Boston
|
|
MIT’s Bob Langer Strikes Again, Wins Priestley Medal
|
Luke Timmerman |
06/13/11 |
Boston
|
|
Bob Langer’s Selecta Wins Support From Diabetes Foundation for Research Collaboration
|
Arlene Weintraub |
06/09/11 |
Boston
|
|
The Bob Langer and Polaris Family Tree: From Acusphere to Momenta to Visterra
|
Gregory T. Huang |
04/19/11 |
Boston
|
|
Taris Bio Taps Third Rock Ventures and Previous Backers in $18.3M Financing Round
|
Ryan McBride |
04/13/11 |
Boston
|
|
Roche Vet Takes CEO Job at Boston’s Enlight Biosciences
|
Ryan McBride |
04/12/11 |
Boston
|
|
Controversial Companies Are Good, VCs Are Getting Active, and the Entrepreneurial Generation Is Rising: 10 Takeaways from Xconomy’s VC65
|
Gregory T. Huang |
04/12/11 |
Boston
|
|
The VC65 Photo Gallery: Happy 65th Birthday, Venture Capital
|
Erin Kutz |
04/08/11 |
Boston
|
|
Thanks to Our VC65 Speakers, Sponsors, and Partners
|
Robert Buderi |
04/08/11 |
Boston
|
|
Come Celebrate 65 Years of Venture Capital in America: Xconomy’s VC65 Blowout at MIT Tomorrow
|
Robert Buderi |
04/05/11 |
Boston
|
|
How to Maximize Startup Success, Get a Free Book, and Make the Most of VC65 on April 6
|
Robert Buderi |
03/28/11 |
Boston
|
|
Buy Your Ticket Now for VC65 on April 6 and Get a Free Copy of Bill Draper’s Book, The Startup Game
|
Robert Buderi |
03/21/11 |
Boston
|
|
Alnylam Settles One Lawsuit, Hit With Another; Living Proof Raises $16M, Tolerx/GSK Drug Fails to Meet Goal, & More Boston-Area Life Sciences News
|
Rebecca Zacks |
03/18/11 |
Boston
|
|
World Energy Backs Retroficiency, American Superconductor Gets Finnish Firm, BuyWithMe Buys LocalTwist, & More Boston-Area Deals News
|
Erin Kutz |
03/16/11 |
Boston
|
|
Living Proof Shines With $16M
|
Erin Kutz |
03/14/11 |
Boston
|
|
VC65 to Feature Tales of Great VCs and Entrepreneurs—Come Wish Venture Capital a Happy Birthday at MIT’s Kresge Auditorium
|
Robert Buderi |
03/08/11 |
Boston
|
|
Pervasis in “Advanced” Talks with Potential Partners for Blood-Vessel Healing Product, CEO Says
|
Ryan McBride |
02/01/11 |
Boston
|
|
Relay: An App for Finding the Next Top Scientists and Discoveries
|
Ryan McBride |
01/04/11 |
Boston
|
|
Page 1 of
3 |
next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.
© 2007-2012, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.
Site produced by Andrew Koyfman with design from Rob Hunter.